Related Experiment Videos
[Childhood myelodysplastic syndromes]
1Fédération de Pédiatrie, Hôpital de Bicêtre, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France. brigitte.bader.meunier@bct.hop.paris.fr
Pathologie-Biologie
|June 28, 2002
Summary
Childhood myelodysplastic syndromes (MDS) are diverse, sometimes progressing to leukemia or spontaneously resolving. Allogeneic bone marrow transplant offers the best cure when treatment is needed.
Area of Science:
- Hematology
- Pediatric Oncology
- Genetics
Context:
- Myelodysplastic syndromes (MDS) in children present as a heterogeneous group.
- Includes primary MDS and secondary forms linked to constitutional or metabolic disorders.
- The adult Franco-American-British (FAB) classification is applicable in 50-100% of pediatric cases.
Purpose:
- To describe the characteristics and management of pediatric myelodysplastic syndromes.
- To highlight the applicability of adult classification systems in children.
- To outline potential disease trajectories and treatment options.
Summary:
- Pediatric MDS encompasses primary and secondary forms, with variable clinical presentations.
- The FAB classification system demonstrates significant applicability in childhood MDS diagnosis.
- Disease progression to acute myeloid leukemia, stabilization, or spontaneous regression are observed outcomes.
- Allogeneic bone marrow transplantation is the primary curative treatment when intervention is indicated.
Impact:
- Provides a comprehensive overview of pediatric MDS for clinicians and researchers.
- Facilitates consistent diagnosis and classification of childhood MDS.
- Informs treatment decisions, emphasizing bone marrow transplantation as a curative option.
- Contributes to understanding the natural history and management of this rare pediatric malignancy.